Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses

Vaccine

Volumn 33, Issue 29, 2015, Pages 3314-3321

  Wohlbold, Teddy John ^a   Nachbagauer, Raffael ^a,b   Margine, Irina ^a   Tan, Gene S ^a   Hirsh, Ariana ^a   Krammer, Florian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

HA stalk; Headless hemagglutinin; Heterosubtypic immunity; Influenza virus; Universal influenza virus vaccine

Indexed keywords

INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS A H6N1; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; CROSS PROTECTION; DISEASE MODEL; IMMUNOLOGY; INFLUENZA A VIRUS; ORTHOMYXOVIRUS INFECTION; PROCEDURES; TREATMENT OUTCOME; VACCINATION;

ANIMALS; CROSS PROTECTION; DISEASE MODELS, ANIMAL; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS; INFLUENZA VACCINES; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; TREATMENT OUTCOME; VACCINATION;

EID: 84931573106     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.038     Document Type: Article

References (50)

1. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003, 21:1776-1779.
2. Tricco A.C., Chit A., Soobiah C., Hallett D., Meier G., Chen M.H., et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med 2013, 11:153.
3. Palese P. Influenza: old and new threats. Nat Med 2004, 10:S82-S87.
4. Krammer F. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J 2015.
5. Krammer F., Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 2013, 3:521-530.
6. Heaton N.S., Sachs D., Chen C.J., Hai R., Palese P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc Natl Acad Sci U S A 2013, 110:20248-20253.
7. Gerhard W., Yewdell J., Frankel M.E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 1981, 290:713-717.
8. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 1993, 67:2552-2558.
9. Tan G.S., Krammer F., Eggink D., Kongchanagul A., Moran T.M., Palese P. A pan-h1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol 2012, 86:6179-6188.
10. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324:246-251.
11. Friesen R.H., Lee P.S., Stoop E.J., Hoffman R.M., Ekiert D.C., Bhabha G., et al. A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 2014, 111:445-450.
12. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333:850-856.
13. Henry Dunand C.J., Leon P.E., Kaur K., Tan G.S., Zheng N.Y., Andrews S., et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J Clin Invest 2015, 125:1255-1268.
14. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
15. Margine I., Hai R., Albrecht R.A., Obermoser G., Harrod A.C., Banchereau J., et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol 2013, 87:4728-4737.
16. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453:667-671.
17. Moody M.A., Zhang R., Walter E.B., Woods C.W., Ginsburg G.S., McClain M.T., et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE 2011, 6:e25797.
18. Krammer F., Pica N., Hai R., Tan G.S., Palese P. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol 2012, 86:10302-10307.
19. Steel J., Lowen A.C., Pena L., Angel M., Solorzano A., Albrecht R., et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009, 83:1742-1753.
20. Krammer F., Albrecht R.A., Tan G.S., Margine I., Hai R., Schmolke M., et al. Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol 2014, 88:3976-3985.
21. Krammer F., Schinko T., Palmberger D., Tauer C., Messner P., Grabherr R. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol Biotechnol 2010, 45:226-234.
22. Krammer F., Pica N., Hai R., Margine I., Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 2013, 87:6542-6550.
23. Krammer F., Margine I., Tan G.S., Pica N., Krause J.C., Palese P. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLOS ONE 2012, 7:e43603.
24. Steel J., Lowen A.C., Wang T.T., Yondola M., Gao Q., Haye K., et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1:1-9.
25. Margine I., Palese P., Krammer F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp 2013.
26. Heaton N.S., Leyva-Grado V.H., Tan G.S., Eggink D., Hai R., Palese P. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies. J Virol 2013, 87:8272-8281.
27. Hai R., Krammer F., Tan G.S., Pica N., Eggink D., Maamary J., et al. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 2012, 86:5774-5781.
28. Dinca L., Neuwirth S., Schulman J., Bona C. Induction of antihemagglutinin antibodies by polyclonal antiidiotype antibodies. Viral Immunol 1993, 6:75-84.
29. Sliepen K., van Montfort T., Melchers M., Isik G., Sanders R.W. Immunosilencing a highly immunogenic protein trimerization domain. J Biol Chem 2015, 290:7436-7442.
30. Weldon W.C., Wang B.Z., Martin M.P., Koutsonanos D.G., Skountzou I., Compans R.W. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS ONE 2010, 5.
31. Graves P.N., Schulman J.L., Young J.F., Palese P. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126:106-116.
32. Salem M.L., Hossain M.S. In vivo acute depletion of CD8(+) T cells before murine cytomegalovirus infection upregulated innate antiviral activity of natural killer cells. Int J Immunopharmacol 2000, 22:707-718.
33. Nachbagauer R., Wohlbold T.J., Hirsh A., Hai R., Sjursen H., Palese P., et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 2014, 88:13260-13268.
34. Ellebedy A.H., Krammer F., Li G.M., Miller M.S., Chiu C., Wrammert J., et al. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 2014, 111:13133-13138.
35. Pica N., Hai R., Krammer F., Wang T.T., Maamary J., Eggink D., et al. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A 2012, 109:2573-2578.
36. Bommakanti G., Citron M.P., Hepler R.W., Callahan C., Heidecker G.J., Najar T.A., et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A 2010, 107:13701-13706.
37. Bommakanti G., Lu X., Citron M.P., Najar T.A., Heidecker G.J., ter Meulen J., et al. Design of Escherichia coli-expressed stalk domain immunogens of H1N1 hemagglutinin that protect mice from lethal challenge. J Virol 2012, 86:13434-13444.
38. Mallajosyula V.V., Citron M., Lu X., Meulen J.T., Varadarajan R., Liang X. In vitro and in vivo characterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin. Proteins 2013, 81:1759-1775.
39. Mallajosyula V.V., Citron M., Ferrara F., Lu X., Callahan C., Heidecker G.J., et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A 2014, 111:E2514-E2523.
40. Lu Y., Welsh J.P., Swartz J.R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A 2014, 111:125-130.
41. Krammer F., Margine I., Hai R., Flood A., Hirsh A., Tsvetnitsky V., et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol 2014, 88:2340-2343.
42. Margine I., Krammer F., Hai R., Heaton N.S., Tan G.S., Andrews S.A., et al. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 2013, 87:10435-10446.
43. Miller M.S., Gardner T.J., Krammer F., Aguado L.C., Tortorella D., Basler C.F., et al. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med 2013, 5:198ra07.
44. Terajima M., Cruz J., Co M.D., Lee J.H., Kaur K., Wrammert J., et al. Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies. J Virol 2011, 85:13463-13467.
45. Dilillo D.J., Tan G.S., Palese P., Ravetch J.V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 2014, 20:143-151.
46. Jegaskanda S., Weinfurter J.T., Friedrich T.C., Kent S.J. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 2013, 87:5512-5522.
47. Jegaskanda S., Job E.R., Kramski M., Laurie K., Isitman G., de Rose R., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 2013, 190:1837-1848.
48. Jegaskanda S., Reading P.C., Kent S.J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J Immunol 2014, 193:469-475.
49. Kirchenbaum G.A., Ross T.M. Eliciting broadly protective antibody responses against influenza. Curr Opin Immunol 2014, 28:71-76.
50. Krammer F., Palese P. Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 2015, 14:167-182.